Although the phase III MANTRA trial of milademetan, an MDM2 inhibitor, failed to meet its primary endpoint, preclinical findings suggest that MDM2 amplification and tumor heterogeneity may contribute to resistance. The gene discussed is MDM2; the disease is neoplasm.